GlassScriptPhysician profile
James J Brown
NPI 1528096971
$11,365.34
in general payments reported to CMS, 2019-2025
16 companies · $413 in 2025
The $413 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $865 · 2020: $525 · 2021: $758 · 2022: $7,322 · 2023: $770 · 2024: $713 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,868 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,867.78 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $8,953.13 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $836.22 | 2019-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $356.52 | 2022-2025 | Ozurdex |
| Genentech USA, INC. | $291.47 | 2022-2024 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $267.27 | 2023-2024 | Syfovre |
| Biogen, INC. | $195.22 | 2023-2024 | Byooviz |
| Astellas Pharma US INC | $102.40 | 2024-2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $98.06 | 2019 | |
| Optos, INC. | $67.56 | 2019 | |
| Bausch & Lomb Americas INC. | $48.73 | 2024 | Xipere |
| Novartis Pharmaceuticals Corporation | $30.25 | 2019-2020 | |
| Neurotech Pharmaceuticals, INC. | $29.49 | 2025 | |
| Rxsight INC | $27.78 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Allergan, INC. | $23.34 | 2022 | |
| Ocular Therapeutix, INC. | $20.44 | 2025 | Dextenza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $17.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$33,333.32 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.